BNTX Stock Analysis: BioNTech SE | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 24.357m USD | 12M Return: -13.6% | US09075V1026 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.7M
Qual. Beats: 0
Rev. Trend: -58.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioNTech SE is a German biotechnology company headquartered in Mainz that develops and commercializes immunotherapies, with its core technology built around messenger RNA (mRNA) platforms. Originally incorporated in 2008, the company gained global recognition through its BNT162 mRNA vaccine developed for SARS-CoV-2, which serves as a foundation for its broader infectious disease and oncology programs.
The company maintains a deep clinical pipeline that extends well beyond COVID-19, with a strong emphasis on oncology candidates across multiple phases of development, including Phase III assets such as Gotistobart (non-small cell lung cancer), Pumitamig (small cell lung cancer and triple-negative breast cancer), and Trastuzumab pamirtecan (metastatic breast cancer). Earlier-stage oncology work targets solid tumors, colorectal cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, mesothelioma, neuroendocrine neoplasms, and pancreatic ductal adenocarcinoma.
In parallel, BioNTech is advancing infectious disease vaccines against pathogens including mpox, tuberculosis, malaria, influenza, and SARS-CoV-2, illustrating how its mRNA platform is applied across therapeutic areas. Listed on NASDAQ under the ticker BNTX since its 2019 IPO, the company operates within the large-cap biotechnology segment, where platform-based developers typically face long regulatory timelines and significant R&D investment before products reach commercialization.
- COVID vaccine revenue declines sharply as demand normalizes
- Oncology Phase III readouts for Pumitamig and Gotistobart approach
- Strong cash reserves fund oncology pipeline expansion and M&A activity
| Net Income: -1.69b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 12.50 > 1.0 |
| NWC/Revenue: 504.7% < 20% (prev 489.1%; Δ 15.64% < -1%) |
| CFO/TA 0.04 > 3% & CFO 736.8m > Net Income -1.69b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (253.3m) vs 12m ago 4.85% < -2% |
| Gross Margin: 70.82% > 18% (prev 79.76%; Δ -8.94% > 0.5%) |
| Asset Turnover: 12.60% > 50% (prev 13.30%; Δ -0.71% > 0%) |
| Interest Coverage Ratio: -86.04 > 6 (EBIT TTM -1.62b / Interest Expense TTM 18.8m) |
| A: 0.66 (Total Current Assets 15.3b - Total Current Liabilities 1.95b) / Total Assets 20.3b |
| B: 0.82 (Retained Earnings 16.6b / Total Assets 20.3b) |
| C: -0.08 (EBIT TTM -1.62b / Avg Total Assets 21.0b) |
| D: 6.87 (Book Value of Equity 17.8b / Total Liabilities 2.58b) |
| Altman-Z'' = 13.66 = AAA |
| DSRI: 0.18 (Receivables 245.1m/1.45b, Revenue 2.64b/2.88b) |
| GMI: 1.13 (GM 79.76% / 70.82%) |
| AQI: 0.91 (AQ_t 0.19 / AQ_t-1 0.21) |
| SGI: 0.92 (Revenue 2.64b / 2.88b) |
| TATA: -0.12 (NI -1.69b - CFO 736.8m) / TA 20.3b) |
| Beneish M = -3.71 (Cap -4..+1) = AAA |
As of October 15, 2026, the stock is trading at USD 88.66 with a total of 1,130,435 shares traded. Over the past week, the price has changed by -6.92%, over one month by -10.32%, over three months by -1.92% and over the past year by -13.60%.
Current recommended Stop Loss: 84.30 (which is 4.9% or 1.2 ATR below the current price).
BioNTech SE has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy BNTX.
- StrongBuy: 13
- Buy: 1
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 116.2 | 31.1% |
Market Cap EUR = 21.7b (24.4b USD * 0.89219999313354 USD.EUR)
P/E Forward = 7.0373
P/S = 9.1912
P/B = 1.215
P/EG = 0.046
Revenue TTM = 2.64b EUR
EBIT TTM = -1.62b EUR
EBITDA TTM = -941.1m EUR
Long Term Debt = 258.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 57.2m EUR (from shortTermDebt, last quarter)
Debt = 541.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 225.4m
Net Debt = -9.20b EUR (calculated: Debt 541.4m - CCE 9.74b)
Enterprise Value = 12.5b EUR (21.7b + Debt 541.4m - CCE 9.74b)
Interest Coverage Ratio = -86.04 (Ebit TTM -1.62b / Interest Expense TTM 18.8m)
EV/FCF = 24.18x (Enterprise Value 12.5b / FCF TTM 518.3m)
FCF Yield = 4.13% (FCF TTM 518.3m / Enterprise Value 12.5b)
FCF Margin = 19.61% (FCF TTM 518.3m / Revenue TTM 2.64b)
Net Margin = -64.02% (Net Income TTM -1.69b / Revenue TTM 2.64b)
Gross Margin = 70.82% ((Revenue TTM 2.64b - Cost of Revenue TTM 771.3m) / Revenue TTM)
Gross Margin QoQ = 8.14% (prev -63.17%)
Tobins Q-Ratio = 0.62 (Enterprise Value 12.5b / Total Assets 20.3b)
Interest Expense / Debt = 3.47% (Interest Expense 18.8m / Debt 541.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.28b (EBIT -1.62b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.85 (Total Current Assets 15.3b / Total Current Liabilities 1.95b)
Debt / Equity = 0.03 (Debt 541.4m / totalStockholderEquity, last quarter 17.8b)
Debt / EBITDA = 9.77 (negative EBITDA) (Net Debt -9.20b / EBITDA -941.1m)
Debt / FCF = -17.74 (Net Debt -9.20b / FCF TTM 518.3m)
Total Stockholder Equity = 18.5b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.06% (Net Income -1.69b / Total Assets 20.3b)
RoE = -9.13% (Net Income TTM -1.69b / Total Stockholder Equity 18.5b)
RoCE = -8.61% (EBIT -1.62b / Capital Employed (Equity 18.5b + L.T.Debt 258.9m))
RoIC = -6.98% (negative operating profit) (NOPAT -1.28b / Invested Capital 18.3b)
WACC = 8.53% (E(21.7b)/V(22.3b) * Re(8.67%) + D(541.4m)/V(22.3b) * Rd(3.47%) * (1-Tc(0.21)))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.98 | Cagr: 2.33%
[DCF] Terminal Value 74.82% ; FCFF base≈518.3m ; Y1≈520.5m ; Y5≈551.3m
[DCF] Fair Price = 69.75 (EV 8.33b - Net Debt -9.20b = Equity 17.5b / Shares 251.2m; r=8.53% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.42 | # QB: 0
Revenue Correlation: -58.33 | Revenue CAGR: -15.38% | SUE: -0.20 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.76 | Chg30d=+0.00% | Revisions=+50% | Analysts=5
EPS current Year (2026-12-31): EPS=-4.78 | Chg30d=-3.31% | Revisions=-17% | GrowthEPS=-896.3% | GrowthRev=-37.7%
EPS next Year (2027-12-31): EPS=-4.89 | Chg30d=+0.17% | Revisions=-17% | GrowthEPS=-2.3% | GrowthRev=+0.5%
[Analyst] Revisions Ratio: +8% (up=5, down=4)